RETRACTED: Unveiling the potential of FOXO3 in lung cancer: From molecular insights to therapeutic prospects
Mohammad Ebrahimnezhad, Amir Valizadeh, Maryam Majidinia, Peyman Tabnak, Bahman Yousefi
Abstract
Lung cancer poses a significant challenge regarding molecular heterogeneity, as it encompasses a wide range of molecular alterations and cancer-related pathways. Recent discoveries made it feasible to thoroughly investigate the molecular mechanisms underlying lung cancer, giving rise to the possibility of novel therapeutic strategies relying on molecularly targeted drugs. In this context, forkhead box O3 (FOXO3), a member of forkhead transcription factors, has emerged as a crucial protein commonly dysregulated in cancer cells. The regulation of the FOXO3 in reacting to external stimuli plays a key role in maintaining cellular homeostasis as a component of the molecular machinery that determines whether cells will survive or dies. Indeed, various extrinsic cues regulate FOXO3, affecting its subcellular location and transcriptional activity. These regulations are mediated by diverse signaling pathways, non-coding RNAs (ncRNAs), and protein interactions that eventually drive post-transcriptional modification of FOXO3. Nevertheless, while it is no doubt that FOXO3 is implicated in numerous aspects of lung cancer, it is unclear whether they act as tumor suppressors, promotors, or both based on the situation. However, FOXO3 serves as an intriguing possible target in lung cancer therapeutics while widely used anti-cancer chemo drugs can regulate it. In this review, we describe a summary of recent findings on molecular mechanisms of FOXO3 to clarify that targeting its activity might hold promise in lung cancer treatment. • Regulated by intricate signaling pathways and protein interactions, FOXO3 may act as a tumor suppressor or oncogenic. • Non-coding RNAs orchestrate a complex regulatory network in lung cancer by influencing FOXO3 expression. • Pharmacologic compounds targeting FOXO3 offer promising outcomes in combating lung cancer by restoring its expression. • FOXO3's role in lung cancer drug resistance highlights its potential as a therapeutic target for overcoming chemotherapy challenges.